Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-08-29
1999-04-06
Lambkin, Deborah C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
564172, 564176, 546104, A61K 3144, C07C23377, C07D21908
Patent
active
058918868
ABSTRACT:
A new treatment schedule for administration of carboxamide anticancer drugs in which the drug is administered in a divided-dose schedule comprising two or more administrations at frequent intervals, for example every hour. Schedules to produce cyclic peaks/troughs in plasma levels are mentioned. The compounds can be used for circumventing multidrug resistance in cancers and may, for example, be used in combination with other cytotoxic drugs, especially non-topo II inhibitors. Treatment of melanoma and advanced colon cancer is included.
REFERENCES:
patent: 4021551 (1977-05-01), Cullen et al.
patent: 4590227 (1986-05-01), Atwell et al.
patent: 4590277 (1986-05-01), Atwell et al.
patent: 4904659 (1990-02-01), Atwell et al.
patent: 5229395 (1993-07-01), Watanabe et al.
Borst et al: Classical and Novel Forms of Multidrug Resistance and the Physiological Functions of P-Glycoproteins in Mammals, p. 289, 295 (1993).
Argiropoulos G, Bates MRM, Cherubim R, Deady LW, Ganagka AM, Baguley BC and Denny WA. Cytotoxic and DNA-Binding Properties of Aminoalkyl Derivatives of di-and triazaphenanthrenes. Anti-Cancer Drug Design, 1992, 7:285-296.
Atwell GJ, Cain BF, Baguley BC, Finlay GJ, Denny WA. Potential antitumor agents. 43. Synthesis and biological activity of dibasic 9-aminoacridine-4-carboxamides, a new class of antitumour agent. J Med Chem., 1984, 27: 1481-1485.
Atwell GJ, Rewcastle GW, Baguley BC, Denny WA. Potential antitumor agents. 50. In vivo solid tumor activity of derivatives of 664-669.
Atwell GJ, Baguley BC, Denny WA. Potential antitumor agents. 55. 6-Phenylphenanthridine-4-carboxamides: a new class of DNA-intercalating antitumor agents. J Med Chem., 1988, 31: 774-779.
Atwell GJ, Bos CD, Baguley BC, Denny WA. Potential antitumor agents. 56. "Minimal" DNA-intercalating ligands as antitumor drugs: phenylquinoline-8-carboxamides. J Med Chem., 1988, 31: 1048-1052.
Atwell GJ, Baguley BC, Denny WA. Potential antitumor agents. 57. 2-Phenylquinoline-8-carboxamides as "minimal" DNA-intercalating antitumor agents with in vivo solid tumor activity. J Med Chem., 1989, 32: 396-401.
Baguley BC. DNA intercalating anti-tumour agents. Anti-Cancer Drug Design, 1991, 6: 1-35.
Baguley BC, Calveley SB, Crowe KK, Fray LM, O'Rourke SA, Smith GP. Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor .alpha. on colon 38 tumours in mice. Eur J Cancer Clin. Oncol., 1989, 25: 263-269.
Baguley BC, Finlay GF, and Ching LM. Resistance mechanisms to topoisomerase poisons: the application of cell culture methods. Oncology Res., 1992, 4(7):267-274.
Bailly C, Denny WA, Mellor LE, Wakelin LPG and Waring MJ. Sequence specificity of the binding of 9-aminoacridine- and amsacrine-4-carboxamides to DNA studied by DNase I footprinting. Biochemistry, 1992, 31, 3514-3524.
Chen KX, Gresh N, and Pullman B. Groove Selectivity in the Interaction of 9-aminoacridine-4-carboxamide antitumor agents with DNA. FEBS Lett., 1987, 224(2):361-364.
Cornford EM, Young D, Paxton JW. Comparison of the blood-brain barrier and liver pentration of acridine antitumor drugs. Cancer Chemother Pharmacol., 1992, 29: 439-444.
Denny WA. DNA-intercalating ligands as anti-cancer drugs: prospects for future design. Anti-Cancer Drug Design, 1989, 4: 241-263.
Denny WA. Acridine-based antitumour agents. In "The Chemistry of Antitumour Agents", (Ed. DEV Wilman). Blackie & Co., London 1990, pp. 1-29.
Denny WA, Atwell GJ, Rewcastle GW, Baguley BC. Potential antitumour agents. 49. 5-substituted derivatives of solid tumor activity. J Med Chem., 1987, 30: 658-663.
Denny WA, Atwell GJ, Baguley BC. "Minimal" DNA-intercalating agents as antitumour drugs: 2-styrylquinoline analogues of amsacrine. Anti-Cancer Drug Design, 1987, 2: 263-270.
Denny WA, Wakelin LPG. Tricyclic carboxamides: relationships between antitumor activity and the geometry and kinetics of binding to DNA. In, "Structure and Expression, vol. 2 DNA and its Drug Complexes" (Eds. RH Sarma and MH Sarma), Adenine Press, NY 1988, pp. 329-337.
Denny WA, Rewcastle GW, Baguley BC, Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of `minimal` DNA-intercalating agents which may not act via topoisomerase II. J Med Chem., 1990, 33: 814-819.
Denny WA, Turner PM, Atwell GJ, Rewcastle GW, and Ferguson LR. Structure activity relationships for the mutagenic activity of tricyclic intercalating agents in Salmonella typhimurium. Mutation Res., 1990, 232: 233-241.
Denny WA. The role of medicinal chemistry in the discovery of DNA-active anticancer drugs: from random searching, through lead development, to de novo design. Chapter 2 in, "Cancer Biology and Medicine, vol. 3: The Search for New Anti-Cancer Drugs" (Eds. M.J. Waring and B. Ponder), Kluwer, London, pp. 19-54 (1992).
Denny WA, Roos IAG and Wakelin LPG. Interrelations between anti-tumour activity, DNA breakage and DNA binding kinetics for 9-aminoacridinecarboxamide antitumour agents. Anti-Cancer Drug Design, 1986, 1: 141-147.
Evans SMH, Young D, Robertson IGC, Paxton JW. Intraperitoneal administration of the antitumour agent bioavailability, pharmacokinetics and toxicity after a single dose. Cancer Chemother Pharmacol., 1992, 31: 32-36.
Ferguson LR, Hill CM, Baguley BC. Genetic toxicology of tricyclic carboxamides, a new class of DNA binding antitumour agent. Eur J Cancer, 1990, 26(6): 709-714.
Ferguson LR and Denny WA. Frameshift mutagenesis by acridines and other reversibly binding DNA ligands. Mutagenesis, 1990, 5(6): 529-540.
Ferguson LR and Denny WA. The genetic toxicology of acridines. Mutation Res., 1991, 258: 123-160.
Finlay, GJ, Baguley BC. Selectivity of carcinoma in human tumour cell lines in vitro. Eur J Cancer Clin Oncol., 1989, 25: 271-277.
Finlay GJ, Wilson WR, Baguley BC. Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs. Eur J Cancer Clin Oncol., 1989, 25(12):1695-1701.
Finlay GF, Baguley BC. Potentiation by phenylbisbenzimidazoles of cytotoxicity of anti-cancer drugs directed against topoisomerase II. Eur J Cancer, 1990, 26(5): 586-589.
Finlay GJ, Marshall E, Matthews JHL, Paull KD, Baguley BC. In vitro DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemother Pharmacol., 1993, 31: 401-406.
Haldane A, Finlay GJ, Gavin JB, Baguley BC. Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent Pharmacol., 1992, 29: 475-479.
Hudson BD, Kuroda R, Denny WA, and Neidle S. Crystallographic and molecular dications: implicaitons for models of DNA binding. J Biomol Stuct Dynamics, 1987, 5(1): 145-158.
Lee HH, Denny WA. An Improved Synthesis of Substituted
Lee HH, Plamer BD, Baguley BC, Chin M, McFadyen WD, Wickham G, Thorsbourne-Palmer D, Wakelin LPG and Denny WA. DNA-directed alkylating agents. 5. Acridinecarboxamide derivatives of (1,2-diaminoethane)dichloroplatinum(II). J Med Chem, 1992, 35: 2983-2987.
Lee HH, Palmer BD, Boyd M, Baguley BC, Denny WA. Potential Antitumor Agents. 64. Synthesis and Antitumor Evaluation of DNA-intercalating agents. J Med Chem., 1992, 35:258-266.
Marshall ES, Finlay GJ, Matthews JHL, Shaw JHF, Nixon J., Baguley BC. Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted human melanoma cells with human melanoma cell lines. J Natl Cancer Inst., 1992 84:(5):340-345.
McKenna, R, Beveridge A, Jenkins, TC, Neidle S, Denny WA. Molecular modeling of DNA-antitumour drug intercalation interactions: correlation of structural and energetic features with biological properties for a series of phenylquinoline-8-carboxamide compounds. Mol Pharmacol., 1989, 35: 720-728.
Moyer SR, and Jurs PC. A Structure-Activity Relationship for the Binding of acridine-4-carboxamides to DNA. Quantitative Structure-Activity Relationships, 1990, 9:333-339.
O'Connor CJ, Emery DP, Tank H, Denny WA and Sunamoto J. Lysis of egg phosphatidylcholine vesicles by tricyclic carboxamide antitumour agents. Chem Biol Int., 1990, 75: 93-104.
Palmer BD, Boyd M, Denny WA. Aromat
Atwell Graham John
Baguley Bruce Charles
Denny William Alexander
Finlay Graeme John
Rewcastle Gordon William
Lambkin Deborah C.
Oswecki Jane C.
Xenova Limited
LandOfFree
Treatment of cancers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of cancers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of cancers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1371629